2. Search Result
Search Result
Results for "

PNH

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

5

Biochemical Assay Reagents

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-48876
    p-NH2-Bn-DOTA

    		Biochemical Assay Reagents Others
    p-NH2-Bn-DOTAis a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA can be used for conjugation of peptides and radionuclides.
    p-NH2-Bn-DOTA
  • HY-158066
    p-NH2-Bn-NOTA hydrochloride hydrate

    		Biochemical Assay Reagents Others
    p-NH2-Bn-NOTA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic NOTA derivative used for tumor pre-targeting. p-NH2-Bn-NOTA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.
    p-NH2-Bn-NOTA hydrochloride hydrate
  • HY-148646A
    p-NH2-CHX-A"-DTPA hydrochloride hydrate

    		Biochemical Assay Reagents Others
    p-NH2-CHX-A"-DTPA (hydrochloride hydrate)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DPTA derivative used for tumor pre-targeting. p-NH2-CHX-A"-DTPA (hydrochloride hydrate) can be used for conjugation of peptides and radionuclides.
    p-NH2-CHX-A
  • HY-148646
    p-NH2-CHX-A"-DTPA

    		Others Others
    p-NH2-CHX-A"-DTPA is a bifunctional chelating agent .
    p-NH2-CHX-A
  • HY-W717760
    p-NH2-Bn-DOTA-tetra(t-Bu ester)

    		Biochemical Assay Reagents Others
    p-NH2-Bn-DOTA-tetra(t-Bu ester)is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-DOTA-tetra(t-Bu ester) can be used for conjugation of peptides and radionuclides.
    p-NH2-Bn-DOTA-tetra(t-Bu ester)
  • HY-W782080
    p-NH2-Bn-oxo-DO3A

    		Biochemical Assay Reagents Others
    p-NH2-Bn-oxo-DO3Ais a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative used for tumor pre-targeting. p-NH2-Bn-oxo-DO3A can be used for conjugation of peptides and radionuclides.
    p-NH2-Bn-oxo-DO3A
  • HY-158003
    COE-PNH2

    		Bacterial Infection
    COE-PNH2 exhibits antibacterial activity against Mycobacterium abscessus (Mab) with MIC90 of 26 μM. COE-PNH2 affects the integrity of the bacterial envelope and mycomembrane. COE-PNH2 reveals intracelluar penetration without mitochondrial toxicity .
    COE-<em>PNH</em>2
  • HY-147297
    Pelecopan

    BCX9930

    		 Complement System Inflammation/Immunology
    Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases .
    Pelecopan
  • HY-P99965
    Crovalimab

    SKY59; RO7112689

    		 Complement System Cardiovascular Disease Metabolic Disease
    Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .
    Crovalimab
  • HY-117930
    Danicopan
    3 Publications Verification

    ACH-4471

    		 Complement System Inflammation/Immunology
    Danicopan (ACH-4471), a selective and orally active small-molecule factor D inhibitor, shows high binding affinity to human Factor D with Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits alternative pathway of complement (APC) activity, has potential to block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .
    Danicopan
  • HY-127105A
    Iptacopan hydrochloride
    3 Publications Verification

    LNP023 hydrochloride

    		 Complement System Metabolic Disease Inflammation/Immunology
    LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. LNP023 inhibits factor B with an IC50 value of 10 nM .
    Iptacopan hydrochloride
  • HY-127105
    Iptacopan
    3 Publications Verification

    LNP023

    		 Complement System Metabolic Disease Inflammation/Immunology
    Iptacopan (LNP023) is a first-in-class, orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 value of 10 nM. Iptacopan shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. Iptacopan targets the underlying cause of complement 3 glomerulopathy (C3G) .
    Iptacopan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: